Metabolomics Market Size & Share, by Product & Services (Instruments, Bioinformatics Tools & Services); Application (Biomarker Discovery, Drug Discovery, Toxicology Testing, Functional Genomics, Personalized Medicine, Nutrigenomics); Indication (Cancer, Cardiovascular Disorders, Neurological Disorders); Techniques (Separation, Detection) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

Growth Drivers

• Growing Acceptance of Metabolomics in Personalized Medicine – Metabolite profiling in biological matrices is a major tool to discover biomarkers and personalized medicine. The metabolomics studies are involved in the identification of several biomarkers that involve complex clinical phenotypes using diverse biological systems. This helps to create personalized medicine to improve drug efficacy and reduce toxicity. Worldwide metabolomics represents more than 95% of the workload in clinical laboratories. Associating metabolomics with genomics, proteomics, and transcriptomics will aid to understand the mechanism of disease, and the pathophysiology of the target clinical phenotype.
• Increased Incidence of Chronic Diseases – Chronic diseases affect health and quality of life. Chronic diseases such as diabetes, cancer, and heart disease are the most common causes of death in the U.S.  As per the Centers for Disease Control, every year 90% of the nation’s USD 3.8 trillion in healthcare costs are attributed to people with chronic diseases and mental health conditions.
• Funding from Government and Private Authorities – The Investment Possibility of the Undiagnosed Disease Network (UDN) announced the establishment of a Metabolomics core that'd enhance clinical and laboratory findings and aid the Network in the diagnosis of patients with unknown disorders. Numerous government financing initiatives have been launched for advanced metabolomics research. For instance, to promote the interpretation of data from metabolomics research, the National Institute of Health (NIH), has granted a grant for USD 1.37 million.
• Technological Advancements in Scientific Instruments – NIST developed a set using human urine materials to help in metabolomics QC materials. The set consists of pooled samples from female and male smokers and non-smokers. The set is qualitatively characterized by liquid chromatography, high-resolution mass spectrometry, and NMR to detect percent differences and metabolite fold changes for the top 20 metabolites in each urine material. The adoption and regular utilization of these QC materials will help to bring harmonization to the metabolomics field in its application in research, diagnostic, testing laboratories, and varied bio-relevant industrial processes.
• Growing Healthcare Infrastructure – The rising demand for new digital products to replace old analog systems in the healthcare sector. Disease diagnosis and medical imaging is increasing the demand for innovation of technologically advanced equipment and installation of diagnostic devices.

Challenges

• High Price of Metabolomic Instruments - The cost and management of a group of analytical tools, that are either collectively quite expensive, or demand a sizeable amount of funds. Depending on the necessary triple, quadrupole, or high-resolution architecture, a modern gas chromatography coupled to mass spectrometry (GC-MS) system costs between USD 200k and USD 600k, a liquid chromatography coupled to mass spectrometry (LC-MS) system costs between USD 300k and USD 800k, and a nuclear magnetic resonance system cost more than USD 800k.
• Need for Multiple Analytical Platforms
• Complexity Increase in Interpreting Data